secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-07-09T12:35:31+00:00
Accession:  0001104659-26-082116
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia completes dose titration in Phase 1 Part 3 of DA-1726 obesity trial; topline data on track for Q4 2026
--------------------------------------------------------------------------------

- All active patients in Part 3A (48 mg) and Part 3B (64 mg) reached highest target doses after titration.
- Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg in 8 weeks, plus reductions in waist circumference and glycemic measures.
- Part 3 enrolls ~40 obese subjects randomized 4:1 active:placebo across two 16-week titration cohorts.
- Topline data from Part 3 remains on track for release in Q4 2026.
- CEO cites favorable tolerability and efficient titration as potential competitive advantage over marketed obesity therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926082116/0001104659-26-082116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926082116/tm2620006d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-082116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer